Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

SAMHSA releases latest statistics on substance misuse including for prescription opioids, heroin, fentanyl, and more.
Agency is taking steps to advance development of new FDA-approved treatments for opioid dependence.
Stanford scientists discover that ketamine's antidepressive effect is tied to the opioid system in the brain.
As the US Congress prepares to return to session after Labor Day, FDA Commissioner Scott Gottlieb, MD, has taken the opportunity to outline his agency’s work on the opioid crisis over the past 8 months.
FDA tackles opioid epidemic by focusing on rational prescribing practices for the treatment of acute pain.
Pennsylvania-based biotech company Braeburn has a PDUFA target date of December 26, 2018 for its buprenorphine injectable aimed at treating opioid use disorder (OUD) in adults.
A new survey shows that migraine sufferers are largely unaware of the new preventive CGRP medication class.
Numerous studies have shown the powerful impact that lifestyle medicine can have on patients as part of an integrative approach.
A new pain assessment tool may be coming soon to clinical trials for better, individualized treatment approaches.
Agency is encouraging developers to innovate against opioid misuse.
PPM's latest special report addresses Pain Research & Care in Women, including:
Resource for Your Practice - A PPM Brief
As pressure and questions mount regarding how to safely care for patients living with chronic pain, FDA Commissioner Scott Gottlieb, MD, released a statement on balancing access to opioids for those patients in need with the agency’s efforts to prevent misuse and abuse of opioids.
close X